dCell Vascular Patch in Peripheral Vascular Surgery Study for CE Mark Submission

An Open Arm Pilot Study to Evaluate the Safety and Performance of the dCell Vascular Patch in Reconstructive Peripheral Vascular Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00958230

Enrollment

Registered

2009-08-13

Start date

2009-08-31

Completion date

2011-11-30

Last updated

2014-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Vascular Occlusion

Keywords

endarterectomy, dCell, Tissue Regenix Ltd, TRL, Vascular Patch, Treatment

Brief summary

The study is designed to produce early safety and performance data in a small group of patients requiring repair of a peripheral vascular endarterectomy (incision into an artery feeding the limbs which requires a patch to repair the incision after removal of an atherosclerotic plaque that was stopping usual blood flow to the limbs). Data is being collected to show the procedure is safe and allows for normal blood flow to be resumed. Data will be used to facilitate CE Mark submission.

Interventions

DEVICEdCell Vascular Patch

Implantation of a dCell Vascular Patch as part of an Endarterectomy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients scheduled for a remote or open peripheral vascular endarterectomy 2. Lack of suitable autologous material to function as closure patch for the arteriotomy 3. Uncomplicated standard elective endarterectomy procedure (per-operative inclusion criteria) 4. Use of dCell™ Vascular Patch as arteriotomy closure material (per-operative inclusion criteria) 5. Patients between 18 and 80 years old, inclusive 6. Haemoglobin \> 9 g/dL and platelet count \> 100,000/mm3 prior to Day 1 7. Other haematological and biochemical parameters within a range acceptable for the administration of general anesthesia prior to Day 1 8. Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures 9. Duly executed, written, informed consent obtained from patient

Exclusion criteria

1. Known serious allergy to contrast agent used for angiography 2. Treatment with any investigational drug or device within 60 days prior to study entry (Day 1) 3. If female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6-12 months 4. Patients receiving a revision of an existing graft 5. Patients demonstrating an active local or systemic infection (WBC \> 15,000/mm3) 6. Any condition which in the judgment of the Investigator would preclude adequate evaluation of dCell™ Vascular Patch's safety and performance 7. Patients on vitamin K antagonists

Design outcomes

Primary

Measure	Time frame
Maintenance of Arterial Patency	6 months for CE Mark, 24 months Post Market Surveillance

Secondary

Measure	Time frame
Complication Rate	6 months for CE Mark, 24 months for PMS

Countries

Hungary, Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026